Secondary osteoporosis during long-term steroid treatment;Osteoporoza wtórna w przebiegu przewlekłej steroidoterapii

Przeglad Menopauzalny

Volumn 6, Issue 6, 2007, Pages 336-343

  Sewerynek, Ewa ^a,b   Bajon, Karolina ^a,b   Stuss, Michał ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Bone mineral density; Osteoporosis; Pain; Prophylactics; Risk of fracture; Steroids; Treatment

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; FLUORIDE SODIUM; GLUCOCORTICOID RECEPTOR; HYDROCHLOROTHIAZIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PLACEBO; RISEDRONIC ACID; STEROID; STRONTIUM RANELATE; VITAMIN D;

ARTICLE; BONE DENSITY; BONE MASS; BONE TISSUE; CALCIUM METABOLISM; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCIURIA; LONG TERM EXPOSURE; OSTEOLYSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; RHEUMATOID ARTHRITIS; SECONDARY HYPERPARATHYROIDISM; SECONDARY OSTEOPOROSIS; SPINE DISEASE;

EID: 38649093947     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Rell-Bakalarska M. Osteoporozy wtórne. Terapia 2006; 3: 47-51.
2. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274-82.
3. O'Berin C, Jia D, Plotki L et al. Glucocorticosteroids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004; 145: 1835-41.
4. Weinstein RS, Jia D, Powers CC, et al. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 2004; 145: 1980-7.
5. Haugeberg G, Griffiths B, Sokoll K B, et al.. Bone loss in patients of methylprednisolone is not negligible: a short term prospective observational study. Ann Reum Dis 2004; 63: 940-4.
6. Adach J, Bensen W, Bianchi F, et al.. Vitamin D and calcium in the prevention of glucocorticoid-induced osteoporosis: a 3 year follow up. J Rheumatol 1996; 23: 995-1000.
7. Kaji H, Yamauchi M, Chihara K, Sugimoto. The threshold of bone mineral density of vertebral fracture in female patients with glucocorticoid induced-osteoporosis. Endocr J 2006; 53: 27-34.
8. Mc Laughlin F, Mackintosh J, Hayes BP, et al. Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography and biochemical markers. Bone 2002; 30: 924-30.
9. Ikeda S, Morishita Y, Tsutsumi H, et al. Reductions in bone turnover, mineral and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticold-treated growing minipigs. Bone 2003; 33: 779-87.
10. Cosman F, Nieves J, Herbert J, et al. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994; 9: 1097-105.
11. Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary excertion in development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32:151-6.
12. Sattler A, Schoppet M, Schaefer J, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004; 74: 103-6.
13. Myers D, Collier F, Minkin C, et al. Expression of functional RANK on mature rat and human osteoclasts. FEBS Lett 1999; 463: 295-300.
14. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-57.
15. Brändstrom H, Björkman T, Ljunggren O. Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal, cells. Biochem Biophys Res Commun 2001; 280: 831-5.
16. Weinstein RS, Chen J, Powers CC, et al. Promotion of osteoclasts survival and antagonism of bisphosphonate-induced osteoclasts apoptosis by glucocorticoids. J Clin Invest 2002; 109: 1041-8.
17. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 2000; 85: 2907-12.
18. Takuma A, Kaneda T, Sato T, et al. Dexamethasone enhances osteoclasts formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclasts progenitors for differentiation into osteoclasts. J Biol Chem 2003; 278: 44667-74.
19. Autio P, Karjalainen J, Risteli L, et al. Effects of an inhaled steroid (budesonide) on skin collagen syntesis of asthma patiens in vivo. Am J Resp Crit Care Med 1996; 153: 1172-5.
20. Hofbauer LC, Riggs BL, Gori F, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140: 4382-9.
21. Saag K. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 2003; 32: 135-57.
22. Harrington JT, Barsh HL, Day S, Lease J. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 2005; 53: 198-204.
23. Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993; 306: 558.
24. Bansen R, Adachi J, Papaioannou A, et al. Evaluation of easily measured risk factors in the prediction of osteoporotic fractures. Musculosceletal Disorders 2005; 6: 47-58.
25. Newman ED, Matzko CK, Olenginski TP, et al. Glucocorticoid-induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006; 17: 1428-34.
26. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44: 1496-503.
27. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996; 39: 1791-801.
28. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis 2005; 64: 176-8.
29. Lorenc RS, Głuszko P, Kaczmarkiewicz E i wsp. Zalecenia postepowania diagnostycznego i leczniczego w osteoporozie. Obniżenie czestości złamań poprzez efektywna profilaktyke i leczenie. Terapia 2007; 9: 23-4.
30. Pearce G, Tabensky DA, Dalmas PD, et al. Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 1998; 83: 801-6.
31. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow up (HERS II). JAMA 2002; 288: 49-57.
32. Amin S, LaValley M, Simms R, Felson DT. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999; 42: 1740-51.
33. Kalatos P, Nagy Z, Kiss L, et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000; 59: 48-52.
34. Sambrook P, Birgmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 1747-52.
35. Legroux-Gerot I, Catanzariti L, Marchandise X, et al. Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine 2004; 71: 51-5.
36. Fiter J, Nolla JM, Navarro MA, et al. Weak androgen levels, glucocorticoid therapy, and bone mineral density in postmenopausal women with rheumatoid arthritis. Joint Bone Spine 2000; 67: 199-203.
37. Hall GM, Daniels M, Doyle D, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499-1505.
38. Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995; 96: 157-66.
39. Lozsadi DA, Peters G, Sadik HY, et al. Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg 2006; 108: 157-62.
40. The Writing Group for the PEPI: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin intervention (PEPI) trial. JAMA 1996; 276: 1389-96.
41. Komulainen M, Kroger H, Tupprainen M, et al. HRT and Vit D in prevention of nonvertebral fractures in postmenopausal women; a 5 years randomized trial. Maturitas 1998; 31: 45-54.
42. Sewerynek E, Karzewnik E. Wpływ terapii skojarzonej na gestość mineralna kości. Prz Menolpauz 2006; 1: 8-11.
43. Drinkwater B, Nilson K, Ott S, Chesnut CH 3rd. Bone mineral density after resumption of menses in amenorrheic athletes. JAMA 1986; 256: 380-2.
44. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006-13.
45. Brown JP, Olszynski WP, Hodsman A, et al. Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids. J Clin Densitom 2001; 4: 363-71.
46. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292-9.
47. Lau EM, Woo J, Chan YH, Li M. Alendronate for the prevention of bone loss in patients on inhaled steroid therapy. Bone 2001; 29: 506-10.
48. Patlas N, Golomb G, Yaffe P, et al. Transplacental effects bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999; 60: 68-73.
49. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003; 14: 259-62.
50. Ringe JD, Dorst A, Faber H, et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford) 2003; 42: 743-9.
51. Adachi JD, Bansen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention corticosteriod-induced osteoporosis. Br J Rheumatol 1997; 36: 255-9.
52. Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996; 58: 73-80.
53. Haguenauer D, Welch V, Shea B, et al. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000; 11: 727-38.
54. Register JY, Seeman E, De Vrenejoul MC, et al. Strontiu ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-22.
55. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
56. Hodsman AB, Kisiel M, Adachi JD, et al. Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH (1-34) therapy in women with severe osteoporosis. Bone 2000; 27: 311-8.
57. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17.
58. Greenspan SL, Bone HG, Ettinger MP, et al. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007; 146: 326-39.
59. Dempster DW, Cosman F, Parisien M, et al. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690-709.
60. Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; 15: 944-51.
61. Rehman Q, Lang TF, Arnaud CD, et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int 2003; 14: 77-81.
62. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-33.
63. Miyakoshi N. Preventive effects of intermittent administration of human parathyroid hormone on steroid-induced osteopenia in rats. J Orthop Sci 1996; 1: 318-28.
64. Oxlund H Řrtoft G, Thomsen J, et al. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 2006; 39: 244-52.
65. Reeve J. Recombinant human parathyroid hormone. Br Med J 2002; 324: 435-6.
66. Sewerynek E. Wpływ współpracy lekarza z pacjentem na efektywność leczenia osteoporozy. Terapia 2006; 3: 43-6.